TiGenix raises up to € 40 million through IPO

Leuven (BELGIUM) - March 9, 2007 - TiGenix, the biomedical company focused on innovative local treatments for damaged and osteoarthritic joints, today announces the details of its planned Initial Public Offering (IPO) and listing on the Eurolist by
Euronext Brussels.

• The offering consists of new shares for up to € 40 million which may be increased by a number of new shares up to 15% of the shares offered in the main offering for the purpose of covering over-allotments, if any.
• The offering is organized as a public offer to retail investors in Belgium and a private placement with institutional investors in Belgium and elsewhere in Europe. 
• The price range is set at € 4.20 to € 5.50 per share. 
• The offering period starts on March 12, 2007 and closes on March 23, 2007, subject to early closing. The prospectus with addendum will be available as of March 12, 2007. 
• Listing and trading of the shares of the company are expected to commence on or about March 26, 2007 on an "as-if-and-when-issued" basis, under the symbol TIG. 
• ING and Piper Jaffray have been appointed as joint bookrunners and joint lead managers, and Petercam as co-lead manager.

More info on TiGenix' website or on the press release